5-BROMO-4,6-DIMETHOXY-2-METHYLPYRIMIDINE, 97.0%, 100mg

[4-(Adamantan-1-yl)phenyl]boronic acid, 97%, 5g

Ethyl 2-([1,1'-biphenyl]-4-yl)-2,2-difluoroacetate, 98%, 250mg

N-bromosuccinimide, min. 98%, for synthesis, 100 g, glass packaging

(R)-4-((((9H-fluoren-9-yl)methoxy)carbonyl)amino)-2-(((benzyloxy)carbonyl)amino)butanoic acid, 95%, 5g

(2E)-1-(3,4-dichlorophenyl)-3-(3-methylthiophen-2-yl)prop-2-en-1-one, 95.0%, 10g

4-Chloro-3,5-dimethyl-1-tosyl-1H-indazole, 97.0%, 1g

tert-Butyl 4-chloro-5,6-dihydropyrido[3,4-d]pyrimidine-7(8H)-carboxylate, 95.0%, 5g

1H-Benzimidazole, 6-(difluoromethoxy)-2-[[(3,4-dimethoxy-2-pyridinyl)methyl]sulfonyl]-, 98%, 500mg

2-(Oxazol-4-yl)aniline, 1g

1-Bromo-2,4,5-trimethylbenzene, 95.0%, 1g

4-((6-NITRO-1H-INDOL-1-YL)METHYL)BENZONITRILE, 95.0%, 500mg

Methyl 4-oxochroman-8-carboxylate, 97.0%, 250mg